Abstract
Protein SUMOylation is a dynamic post-translational modification which is involved in a diverse set of physiologic processes throughout the cell. Of note, SUMOylation also plays a role in the pathobiology of a myriad of cancers, one of which is glioblastoma (GBM). Accordingly, herein, we review core aspects of SUMOylation as it relates to GBM and in so doing highlight putative methods/modalities capable of therapeutically engaging the pathway for treatment of this deadly neoplasm.
Keywords:
SUMO1-3; SUMOylation; glioblastoma (GBM); post-translational modifications (PTMs).
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Brain / drug effects
-
Brain / metabolism
-
Brain / pathology
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / metabolism*
-
Brain Neoplasms / pathology
-
Glioblastoma / drug therapy*
-
Glioblastoma / metabolism*
-
Glioblastoma / pathology
-
Humans
-
Molecular Targeted Therapy / methods
-
Protein Processing, Post-Translational / drug effects
-
Small Ubiquitin-Related Modifier Proteins / metabolism
-
Sumoylation / drug effects*
Substances
-
Antineoplastic Agents
-
Small Ubiquitin-Related Modifier Proteins